Genomics

Luk Vandenberghe

Luk H. Vandenberghe, PhD, to receive Foundation Fighting Blindness Award

August 15, 2017

Luk H. Vandenberghe, PhD, along with collaborator and lead author Rob Collin, PhD, of Radboud University Medical Center, has been selected to receive the 2017 Ed Gollob Board of Directors’ Award from the Foundation Fighting Blindness (FFB). This award is presented annually in recognition of significant research advancements. According to the FFB, their winning paper, “In vitro and in vivo rescue of aberrant splicing in CEP290-

Read more about Luk H. Vandenberghe, PhD, to receive Foundation Fighting Blindness Award
Luk Vandenberghe

Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear

September 12, 2016
  • The strategic licensing agreement between Lonza and Massachusetts Eye and Ear® underscores Lonza’s position as a leading AAV manufacturing service provider and offers customers unprecedented technology and services to commercialize next generation gene therapies.
  • The Anc-AAV vector platform has the potential to overcome pre-existing immunity in order to treat more patients compared with other viral vectors currently in development.
  • Anc80, the lead novel Anc-AAV available for sublicensing, is a potent gene therapy vector capable of superior gene expression levels in
Read more about Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear